VIP is an appraisal, not an inspection

A quality team that reads FDA's Voluntary Improvement Program as a fast-track to fewer inspections has the mechanism roughly right and the guarantee wrong. This blog has already covered CP 7382.850, the compliance program that now governs a mandatory FDA device inspection under the agency's own statutory authority. VIP runs alongside that program, not instead of it: a voluntary, third-party appraisal of a site's own quality management maturity that FDA formally recognized in guidance in September 2023, and that can shift how the agency plans its inspection schedule — without ever becoming the inspection itself, and without any promise that enrolling removes a site from one.

A pilot CDRH didn't build alone

CDRH launched what became VIP in 2017, in partnership with the Medical Device Innovation Consortium and the CMMI Institute, as a pilot aimed at giving manufacturers credit for demonstrated quality maturity rather than judging a site purely on inspection findings. The pilot moved to a fully operational program in 2021, and FDA formalized its own engagement with it through a guidance document, Fostering Medical Device Improvement: FDA Activities and Engagement with the Voluntary Improvement Program, finalized in September 2023. That guidance is the primary source worth citing in a readiness file — not a vendor's description of the appraisal itself — because it's the document that actually states what FDA committed to doing with the results.

FDA doesn't run the appraisal

The appraisal itself isn't an FDA activity at all. It runs on ISACA's Medical Device Discovery Appraisal Program, a version of the Capability Maturity Model Integration framework adapted for device manufacturing, administered through MDIC and conducted by independent appraisal teams rather than FDA investigators. A site enrolls, gets appraised against the maturity model's own practice areas, and receives its own findings back — a structurally different event from an FDA investigator walking a facility against CP 7382.850's six QMS areas and four other applicable FDA requirements, even though both exercises are, in the broadest sense, looking at the same quality system.

What enrollment actually buys

FDA has said participation in VIP informs its own risk-based approach to inspection planning and resource allocation, across routine surveillance, pre-approval, and post-market inspection alike. That's a real input into how FDA allocates a finite inspection budget across thousands of registered establishments — not a rule that an enrolled site skips its next inspection, and not a substitute for the inspection authority the FD&C Act's section 704 gives FDA over any registered device establishment. A firm that treats VIP enrollment as a standing exemption from CP 7382.850 has confused one factor in a planning model for a guarantee the guidance never made.

Voluntary cuts both ways

Nothing compels a manufacturer to enroll, and nothing about declining to enroll changes a site's inspection posture under the mandatory program — a site that has never touched VIP is inspected exactly the way CP 7382.850 already describes. The two tracks answer different questions: CP 7382.850 asks whether a specific site currently meets applicable FDA requirements, sampled against product risk; VIP asks how mature a site's own quality management practices are relative to a maturity model, independent of any specific finding. A site can score well on one and still draw a finding on the other, because they're not measuring the same thing. Enrollment is also site-specific, not a company-wide status — a manufacturer with several registered establishments can have one site enrolled in VIP's appraisal cycle and another with no VIP history at all, each carrying its own separate inspection posture under CP 7382.850 regardless of what the other has done.

Not a credential a submission can cite

ASCA accreditation, covered elsewhere on this blog, changes what a 510(k) submission itself can carry — a specific declaration of conformity and summary test report FDA built the program to accept. VIP doesn't work that way. Enrollment and appraisal status aren't submission content; there's no field in a 510(k), a PMA, or the QMSR itself where a manufacturer cites a VIP appraisal to satisfy a premarket or quality requirement. The program's entire effect runs through FDA's own internal inspection planning, not through anything a manufacturer files, which is exactly why a regulatory file that treats a VIP appraisal report like a piece of submission evidence is reaching for a use the program was never built to serve.

Where this meets the file

An inspection-readiness tracker that files VIP status and CP 7382.850 history under one “inspection standing” column is hiding the distinction that actually matters: VIP enrollment and its maturity-appraisal history belong in their own record, kept at the site level, separate from the site's own inspection history and its own NAI, VAI, or OAI outcome, since one is a voluntary input to planning and the other is the regulatory finding itself. A quality-program tracker built to keep the two histories distinct is previewed in the launch catalog. If your site has enrolled in VIP and found this distinction drawn differently, the shelf takes that correction directly.